Triastek Secures RMB 150 Million in Pre-C Financing to Accelerate Commercialization of 3D-Printed Drug Pipeline

VCBeat has learned that on September 28, Nanjing Triastek Medical Technology Co., Ltd. (hereinafter referred to as “Triastek”) announced the completion of its RMB 150 million Pre-C round financing. The proceeds will be primarily used to accelerate the clinical research of its 3D-printed drug pipeline and the commercialization of its 3D printing drug technology. This round was led by Shanghai Guoxin Investment And Development Co.,Ltd., with follow-on investments from Gaomai United Family Office and Mr. Zheng Xiaodong, Chairman of Tofflon Science and Technology Group Co., Ltd., an existing shareholder. China Renaissance served as the exclusive financial advisor for this financing round.

Previously, TRIASTEK completed six rounds of financing, with investors including Tasly Group, Morningside Venture Capital, Volcanic Stone Investment, Daotong Investment, Yunqi Capital, Mr. Zheng Xiaodong, Matrix Partners China, CPE Yuanfeng, Shanghai Science and Technology Innovation Fund, Qinzhi Capital, and other renowned institutions and individuals.

As a 3D-printed drug technology platform company, TRIASTEK pioneered Melt Extrusion Deposition (MED^®) 3D printing processes for pharmaceuticals, combined with digital formulation development methods, enable complex drug delivery and programmed release. In addition to Melt Extrusion Deposition (MED), TRIASTEK continues to develop new manufacturing processes, including semi-solid extrusion, micro-injection molding, and micro-droplet jetting technologies. When integrated with MED technology, these approaches provide more diverse solutions for the delivery and development needs of oral peptide products, gastroretentive products, and highly toxic or highly potent drugs.

As a technology provider for digital pharmaceutical manufacturing processes, TRIASTEK is exploring the diverse application scenarios of 3D drug printing technology. We engage in extensive commercial collaborations with global pharmaceutical companies, encompassing both product-level partnerships and technical solution cooperations. To date, we have established partnerships with numerous multinational corporations and domestic pharmaceutical enterprises, including Eli Lilly, Boehringer Ingelheim, Merck, Siemens, and Shufang.

After eight years of technological innovation and industrial application, TRIASTEK has achieved four “firsts” in the global field of 3D-printed pharmaceuticals: First, it ranks first in the number of patents, accounting for more than 20% of all patent applications in this field. Second, it leads in the number of products; among the four 3D-printed drug products worldwide that have entered or completed regulatory submission, TRIASTEK has three products that have obtained four Investigational New Drug (IND) approvals from China and the United States. Third, it boasts the highest production capacity for 3D-printed drug manufacturing lines, having established its own GMP-compliant 3D-printed drug production center, with the first continuous production line capable of an annual output of 75 million tablets. Fourth, it is the only Chinese pharmaceutical company selected for the U.S. FDA’s Emerging Technology Program (ETP).

Dr. Senping Cheng, Founder and CEO of TRIASTEK“He expressed his gratitude to Shanghai Guoxin Investment And Development Co.,Ltd., Gaomai United Family Office, Mr. Zheng Xiaodong, and the company’s existing shareholders for their support. As multiple self-developed products from TRIASTEK enter clinical trials and collaborations with numerous pharmaceutical companies are established, we will comprehensively advance the commercialization of our technologies and products. By joining hands with more global partners, we aim to drive the pharmaceutical industry toward digital product development and intelligent manufacturing.”

Mr. Lu Zhen, CEO of Shanghai Guoxin Investment And Development Co.,Ltd.“The 3D printing technology for pharmaceuticals offers advantages over traditional manufacturing methods, including continuous production, rapid scale-up, and superior efficacy, positioning it as the future direction for advanced drug formulations. TRIASTEK holds a globally leading position in the field of 3D-printed medicines and is progressively gaining recognition from regulatory authorities and customers. We are delighted to lead this round of financing for TRIASTEK and look forward to the company expanding its collaborative scope, continuously achieving technological iterations, and becoming a benchmark enterprise in China’s advanced drug formulation sector.”

VCBeat United Family Officestated: “Gaomai Capital is optimistic about TRIASTEK’s independently developed, globally leading end-to-end technology platform, which can address challenges that are difficult to resolve in traditional pharmaceutical development, such as gastric retention and the druggability of poorly soluble molecules. By supporting pioneering technology companies like TRIASTEK, Gaomai Capital helps family capital achieve high-quality succession while giving back to society.”

Mr. Zheng Xiaodongstated, “3D printing represents a new direction in pharmaceutical manufacturing advocated by the FDA, and we have been closely monitoring it since 2011. We are delighted to see TRIASTEK advance this emerging technology from concept to commercial production. Tofflon will collaborate with TRIASTEK to support the modernization of China’s pharmaceutical industry.”

Ms. Jiang Jiajia, Managing Director of the Healthcare and Life Sciences Division at China Renaissancestated: “Congratulations to TRIASTEK on the successful completion of its latest round of financing. The current landscape of innovative drug R&D is experiencing robust growth, with an endless stream of new molecules and novel therapies presenting increasingly demanding and complex challenges for drug development. We firmly believe that TRIASTEK’s innovative 3D printing technology for pharmaceuticals holds vast application potential. We will continue to support the company as it scales new heights, and we look forward to seeing TRIASTEK’s innovative technologies facilitate the successful development of a growing number of innovative drug products and accelerate the realization of clinical benefits.”

Global Leader in 3D-Printed Pharmaceuticals, Pioneer of Next-Generation Digital Pharmaceutical Manufacturing.

TRIASTEK was established in July 2015, with the mission of “innovation to enhance drug quality, advance the industry, and improve human health,” pioneering Melt Extrusion Deposition (MED^®) 3D-printed drug manufacturing processes enable digital development and continuous production of pharmaceuticals, fundamentally transforming the methods of drug delivery, development, and manufacturing.

Leveraging our proprietary 3D-printed drug technology, we design and develop transformative medications for patients; we also collaborate with global pharmaceutical companies to address challenging formulation issues, accelerate the development of new drug products, and enhance product quality.

TRIASTEK’s vision is to become the world’s most influential intelligent pharmaceutical company.

Shanghai Guoxin Investment And Development Co.,Ltd. was established in 2000 with a registered capital of RMB 4 billion. As a market-oriented equity investment platform under Shanghai State-owned Assets Operation Co., Ltd., it has long focused on the healthcare industry, accumulating extensive experience in equity investment and demonstrating strong capabilities in project screening, investment, and management. The firm has successfully invested in dozens of well-known domestic pharmaceutical, medical device, and CDMO companies. Adhering to its business philosophy of “discovering value, creating value, and growing together with outstanding enterprises,” Guoxin Investment will continue to play a significant role in implementing Shanghai International Group’s strategic mandate to empower the real economy with financial capital and support the construction of Shanghai as a global science and technology innovation center.

Gaomai United Family Office, established in 2016, is a fund-of-funds for equity allocation that maintains a high degree of interest alignment with its Limited Partners (LPs). It currently has investments across both RMB and USD assets, as well as primary and secondary markets. Since its inception, Gaomai has consistently adhered to long-termism, believing that technological innovation will make the world a better place. It firmly supports outstanding early-stage hard-tech startup teams, helping family capital achieve high-quality succession while giving back to society through rational investment.

Mr. Zheng Xiaodong is the Chairman of Tofflon Science and Technology Co., Ltd. (SZ: 300171). Established in 1993, Tofflon is a comprehensive pharmaceutical equipment supplier that provides integrated solutions encompassing pharmaceutical processes, core equipment, and system engineering to pharmaceutical companies worldwide. Its products are applied in areas such as injectables, solid dosage forms, chemical active pharmaceutical ingredients (APIs), bioengineering, traditional Chinese medicine (TCM), healthcare, and food. Looking ahead, Tofflon aims to evolve from a “system solution provider” into a “deliverer of smart pharmaceutical factories,” serving the global pharmaceutical industry.